A Transformative Compound
CYT-1010 is the first member of a new class of drugs, the endomorphins, to reach clinical development. It produces pain relief through a novel mechanism of action on the endomorphin (EM) receptor.
Our lead compound, CYT-1010, is entering Phase 2 clinical development, following a successful Phase 1 study in humans. This breakthrough pain medicine has shown reduced potential for addiction and significantly less risk of respiratory depression, relative to treatment with traditional pain medicines.
Endomorphins are naturally produced by the human brain and are not structurally related to traditional treatments such as the classical opioids. The endomorphins preferentially activate the EM receptors of the central nervous system to block pain, while avoiding some of the side effects of current analgesic products.
In addition, in breakthrough research, the endomorphins were demonstrated to greatly reduce recovery time from pain following surgery by over 75% compared to morphine. This significant finding is thought to be mediated by the anti-inflammatory properties of the endomorphin, in distinction to the pro-inflammatory properties of morphine.
Pre-clinical trials on CYT-1010 have shown:
- 3-4 times more potent pain relief than morphine
- Potent anti-inflammatory benefits
- Substantially reduced abuse potential
- Profoundly reduced respiratory depression
CYT-1010 can address the challenges of treating moderate to severe pain without the social and economic impacts of current options.